财通证券也指出，继续看多创新药海外BD趋势和国内政策新增量共振带来的产业链地位提升，具有高 科技属性的创新药公司将更受市场青睐。关注具有真创新能力的新药公司，将具备更大的估值弹性。此 外，周期性回暖带来CXO、科学服务等上游机会；关注AI医疗的β机会。 港股通产品方面，港股通创新药ETF工银(159217) 紧密跟踪国证港股通创新药指数，值得关注。Wind数 据显示，截至2025年6月30日，港股通创新药ETF工银管理费率为0.40%，托管费率为0.07%，处于同跟 踪标的类中最低水平。同时，港股通创新药ETF工银近2月跟踪误差为0.8395%，处于同跟踪标的类中最 低水平，显示该ETF对指数的紧密跟踪。 风险提示：基金管理人依照恪尽职守、诚实信用、谨慎勤勉的原则管理和运用基金财产，但不保证基金 一定盈利，也不保证最低收益。基金的过往业绩并不预示其未来表现,基金管理人管理的其他基金的业 绩并不构成基金业绩表现的保证。科创医药ETF基金属于股票型基金，风险与收益高于混合型基金、债 券型基金与货币市场基金。该基金为指数基金，主要采用完全复制策略，跟踪标的指数市场表现，具有 与标的指数、以及标的指数所代表的股票市场 ...

创新药重回聚光灯下。 今年以来，医药板块表现亮眼，尽管近期有所回撤，但自4月9日反弹开始，在市场震荡中走出了独立行情。A股、港股创新药更是持续走强，在经历过四年 医药调整煎熬后，随着行业的修复期开始，不仅是医药主题产品关注度陡增，据公募一季报，机构加仓医药生物产业链相关标的。 | 夜易养商 | | 报告期: | 2025 1 | 一季 > | 宣传 V | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 交易佣金(汇总) | 0 | | | | | | | | | | | | 交易佣金(明细) | B | 序号 | 代码 | 57 名称 | 57 报告期 57 | 定期报告实际披露日期 | 57 | 持股机构家数 7 | 持股数量(万股)了 | ↓持股市值(万元) | 占流通A | | 交易佣金统计(按基金)日 | | 1 | 688578 SH | 艾力斯 | 2025-03-31 | 2025-04-24 | | 26 | 2.221.5594 | 189.499.02 | | ...

Core Viewpoint - The record-breaking licensing agreement between 3SBio and Pfizer, valued at up to $60.5 billion, marks a significant milestone for Chinese pharmaceutical companies in the global market [1][2]. Group 1: Company Developments - 3SBio announced an exclusive licensing agreement with Pfizer for its PD-1/VEGF bispecific antibody SSGJ-707, granting Pfizer global rights (excluding mainland China) for development, production, and commercialization [1]. - The agreement includes an upfront payment of $12.5 billion, which sets a new record for upfront payments for Chinese dual antibodies going abroad, along with potential milestone payments of up to $48 billion based on development, registration, and sales [1]. - The drug SSGJ-707 has received breakthrough therapy designation from the National Medical Products Administration for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with PD-L1 expression [1]. Group 2: Market Impact - Following the announcement, 3SBio's stock surged by 32.28%, while its A-share counterpart, 3SBio Guojian, rose by 19.99%, reflecting heightened investor interest in the innovative drug sector [2]. - Other innovative drug stocks in the Hong Kong market also saw significant gains, with Rongchang Bio up 16.19% and Hansoh Pharmaceutical up 5.74% [2]. - The innovative drug sector's momentum led to increased trading activity in related ETFs, with one ETF recording a transaction volume of 28.28 billion yuan and closing up 5.16% [2]. Group 3: Industry Trends - According to Wanlian Securities, the domestic innovative drug sector is expected to benefit from favorable policies and industry trends, leading to a valuation recovery [3]. - The importance of Chinese pharmaceutical companies is growing in international academic conferences, with many multinational corporations incorporating Chinese products into their core pipelines [3]. - Despite recent market fluctuations due to U.S. drug pricing policies, several domestic brokerages maintain a positive outlook on the growth potential of innovative drug companies in both the Hong Kong and A-share markets [3].

ETF开盘涨跌不一，超大盘ETF(510020)领涨10.00%，碳中和50ETF(159861)涨1.70%，港股通创新药 ETF工银(159217)涨1.28%，养老ETF(516560)领跌0.75%，黄金股票ETF基金(159322)跌0.72%，港股国 企ETF(513810)跌0.71%。 打包市场龙头，抢反弹就买指数ETF>> ...